Skip to main content
ArcticZymes Technologies logo

ArcticZymes Technologies — Investor Relations & Filings

Ticker · AZT ISIN · NO0010014632 LEI · 5967007LIEEXZXGR7K47 BR Manufacturing
Open in API
Filings indexed 968 across all filing types
Latest filing 2021-04-22 Earnings Release
Country NO Norway
Listing BR AZT

About ArcticZymes Technologies

https://arcticzymes.com/

ArcticZymes Technologies is a life sciences company specializing in the development, manufacturing, and commercialization of novel recombinant enzymes. Leveraging over 30 years of expertise, the company discovers and engineers enzymes from cold-adapted Arctic marine organisms. These enzymes are designed to solve specific challenges in molecular applications, demonstrating high efficiency in demanding conditions such as low temperatures and high salinity. The product portfolio, including Salt Active Nucleases (SAN) and Cod Uracil-DNA Glycosylase, serves global partners in molecular diagnostics, gene therapy, vaccine production, and biomanufacturing. All products are manufactured at its ISO 13485 certified facility, ensuring high quality and performance for research and commercial use.

Recent filings

Filing Released Lang Actions
ArcticZymes Technologies Q1 2021 Results
Earnings Release Classification · 100% confidence The document is titled 'ArcticZymes Technologies Q1 2021 Results' and provides key financial highlights (sales, EBITDA, cash flow) for the first quarter of 2021, along with commentary from the CEO. This content structure strongly indicates an initial announcement of periodic financial results, which aligns with the definition of an Earnings Release (ER). Although it mentions a presentation and webcast, the primary content delivered is the summary of the quarterly performance, not just the announcement of the report's availability (which would be RPA/RNS). Since it is a comprehensive summary of quarterly results, it is classified as ER, rather than the more detailed Interim Report (IR). Q1 2021
2021-04-22 English
ArcticZymes Technologies Q1 2021 Presentation
Earnings Release Classification · 99% confidence The document text explicitly mentions "Q1 2021" highlights, financial performance (sales, EBITDA), business updates across segments (Therapeutics, Research & Diagnostics), operational progress (SAN Upscaling), and an outlook for 2021. This structure is characteristic of an Earnings Release (ER) or an Interim/Quarterly Report (IR). However, the document is highly summarized, focusing on key metrics and updates rather than comprehensive financial statements typically found in a full Interim Report (IR). Crucially, the very end of the document states: "Annual General Meeting 20th May 2021". This suggests the presentation material is likely related to the AGM, but the content itself is a summary of quarterly results. Given the focus on quarterly highlights and the presence of an agenda/Q&A session structure, it strongly resembles an Earnings Release (ER) presentation or a document prepared for an AGM that heavily features the latest quarterly results. Since it is a summary of Q1 results, ER is the most fitting primary classification for the content type. If it were a full, detailed report, IR would be chosen. If it were the formal minutes or voting results of the AGM, AGM-R or DVA would be chosen. As it is a presentation of quarterly results, ER is the best fit. Q1 2021
2021-04-22 English
ArcticZymes Technologies Q1 2021 Presentation
Report Publication Announcement Classification · 99% confidence The document is titled 'ArcticZymes Technologies Q1 2021 Presentation' and explicitly mentions presenting an 'interim report for the first quarter 2021'. The text is very short (417 characters) and concludes with 'Please find the presentation attached.' This strongly indicates that the document itself is not the full Interim Report (IR) but rather an announcement about the presentation and the availability of the accompanying materials (the presentation slides). Since it announces the publication of presentation materials related to quarterly results, the most fitting category is Investor Presentation (IP). Although it relates to an interim report, the document's nature is the presentation itself, not the comprehensive financial report (IR) or just the earnings release highlights (ER). Given the context of a presentation being attached, IP is the best fit over RPA, which is usually for the formal report publication itself.
2021-04-22 English
ArcticZymes Technologies ASA: Invitation to presentation of Q1 2021 results
Report Publication Announcement Classification · 98% confidence The document is titled 'ArcticZymes Technologies ASA: Invitation to presentation of Q1 2021 results'. It explicitly states that the Q1 2021 report will be available at 07:00 a.m. on April 22, 2021, and invites participants to a presentation/webcast about these results. Since the document itself is an invitation/announcement about the upcoming release and presentation of the Q1 2021 report, and not the comprehensive report (IR) or the earnings highlights (ER) itself, it fits the definition of a Report Publication Announcement (RPA). The document length (1574 chars) is very short, supporting the RPA classification over the actual report classification.
2021-04-15 English
ArcticZymes Technologies Successfully Upscales SAN HQ Enzyme Production
Regulatory Filings Classification · 95% confidence The document is a press release dated March 26, 2021, announcing a specific operational achievement: the successful upscaling of SAN HQ enzyme production. It details the impact on supply, customer demand, and future availability (Q2). This type of announcement, focusing on operational milestones, growth, and business updates rather than formal financial results (ER/IR) or mandatory regulatory filings (10-K/DEF 14A), typically falls under general corporate news or regulatory announcements. Since it is not a formal financial report, a management discussion, a dividend notice, or a director dealing report, the most appropriate classification is the general regulatory/news announcement category, RNS, as it is a formal communication to the market about a significant business event.
2021-03-26 English
ArcticZymes Technologies Successfully Upscales SAN HQ Enzyme Production
Earnings Release Classification · 99% confidence The document is a short press release dated March 26, 2021, announcing a specific operational achievement: the successful upscaling of SAN HQ enzyme production. It highlights growth, customer demand, and future availability ('commercially available to our customers from early Q2'). This type of announcement, focusing on operational milestones, product development progress, or minor business updates that don't fit the strict definitions of Earnings Release (ER), Capital Update (CAP), or Major Shareholding (MRQ), typically falls under general Regulatory Filings (RNS) or sometimes an Earnings Release if it were tied to a specific reporting period's results. Since it is an announcement of an operational success and supply continuity rather than formal financial results or a mandatory disclosure like a director's dealing or dividend, RNS is the most appropriate general regulatory category, as it is a non-standard, company-specific update. Q1 2021
2021-03-26 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.